ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Lonza Will Boost Conjugate Capability

by Michael McCoy
January 14, 2013 | APPEARED IN VOLUME 91, ISSUE 2

The Swiss pharmaceutical chemicals firm Lonza plans to invest $15 million to expand antibody-drug conjugate (ADC) production capacity in Visp, Switzerland. Lonza calls itself a pioneer in the manufacturing of ADCs, which are now being tested against cancer in dozens of clinical trials. The firm says the project will double large-scale ADC capacity at the site when it is completed in the second quarter of 2014.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment